Clinical Trial Detail

NCT ID NCT03610490
Title Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

ovarian cancer

pancreatic ductal adenocarcinoma

ovarian carcinosarcoma

colorectal adenocarcinoma

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes

Age Groups: adult senior

No variant requirements are available.